Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01711515 · ClinicalTrials.gov registry record · Phase 1
Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT01711515: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01711515 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01711515, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of ipilimumab when given after chemoradiation therapy in treating patients with stages IB2-IIB or IIIB-IVA cervical cancer. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Monoclonal antibodies, such as ipilimumab, may find tumor cells and help carry tumor-killing substances to them. Giving ipilimumab together with chemoradiation therapy may be a better way treat cervical cancer.
Interventions
- DRUG Cisplatin
- RADIATION External Beam Radiation Therapy
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Ipilimumab
- RADIATION Internal Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-10-01 |
| Est. Completion | 2020-07-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01711515
The ClinicalTrials.gov registry entry for NCT01711515 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT01711515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01711515 about?
NCT01711515 is a clinical study titled "Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer". This phase I trial studies the side effects and best dose of ipilimumab when given after chemoradiation therapy in treating patients with stages IB2-IIB or IIIB-IVA cervical cancer. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by kil...
What is the current status of trial NCT01711515?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2012-10-01. Estimated completion is 2020-07-17.
What interventions are being tested in trial NCT01711515?
The interventions under investigation include: Cisplatin (DRUG), External Beam Radiation Therapy (RADIATION), Laboratory Biomarker Analysis (OTHER), Ipilimumab (BIOLOGICAL), Internal Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT01711515?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.